Centessa Pharmaceuticals plc (CNTA)
Jun 24, 2026 - CNTA was delisted (reason: acquired by LLY)
40.50
+0.32 (0.80%)
Inactive · Last trade price on Jun 23, 2026
Centessa Pharmaceuticals Revenue
In the year 2025, Centessa Pharmaceuticals had annual revenue of $15.00M.
Revenue (ttm)
$15.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
6.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCNTA News
- 23 days ago - Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales - GlobeNewsWire
- 6 weeks ago - Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PRNewsWire
- 2 months ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 2 months ago - Centessa Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 2 months ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 3 months ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 3 months ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 3 months ago - Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly - GlobeNewsWire